|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
BTG Interventional Medicine (EKOS)
| | | Phone: | (425) 415-3100 | Fax: | (425) 415-3104 | Year Established: | 1996 | Employees: | 150 | Ticker: | BTG | Exchange: | LSE | Main Contact: | Lori Melkerson, VP, Operations | | Other Contacts: | Mike Wolniewicz, VP, Engineering Anastasia Mironova, VP, Marketing Tony Litwiller, VP, Sales Curtis Genstler, MD, VP, Systems Integration Curtis Genstler, MD, VP, Systems Integration Minda Evans, Director, Business Operations
| | Company Description | BTG Interventional Medicine, formerly EKOS Corp, is part of BTG plc, a global specialist healthcare company. Their growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots, and varicose veins.
On Nov. 20, 2018, Boston Scientific announced it had reached an agreement to acquire BTG for $4.2 billion. The transaction is expected to close in the first half of 2019. | |
|
|
|
|
|